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Objectives: Peripheral arterial disease is associated with significant adverse out-
comes, especially in patients with critical limb ischemia (CLI; stages III and IV). At 
6 months, the risk of amputation is 35%, and mortality 20%. In patients unsuitable 
for interventional therapy, treatment with prostanoids may help reduce the risk of 
adverse outcomes. We aimed to assess the average cost of alprostadil (prostaglan-
din E1) as treatment for patients with CLI compared with lumbar sympathectomy 
from the perspective of The Mexican Social Security Institute (IMSS). MethOds: 
In a clinical trial, alprostadil and lumbar sympathectomy showed similar response 
rates (Petronella P, et al. Nutr Metab Cardiovasc Dis 2004;14:186–92).Therefore, we 
conducted a cost minimization analysis based on the direct medical costs of alpros-
tadil (40 µg twice-daily or 60 µg once-daily) administered over 28 days versus lumbar 
sympathectomy. Relevant costs included acquisition and infusion for alprostadil, 
and surgical procedure besides hospitalization (9 days) for lumbar sympathectomy. 
Unit cost for infusion was assumed to be equivalent to an emergency visit at first 
level of care at IMSS; unit cost of the surgical procedure and standard hospital stay 
(per day) correspond to the official values for these items at the second level of care 
at IMSS. UCB Pharma provided the cost for alprostadil. All costs are in 2013 Mexican 
pesos (MXN; 12.88 MXN = 1 USD, 17.23 MXN = 1 Euro). Results: Costs per patient 
would be lower with both alprostadil 40 µg twice-daily ($59,640) and alprostadil 
60 µg once-daily ($37,884) than with lumbar sympathectomy ($66,084), leading to 
savings of $6,444 (9.8%) and $28,200 (42.7%), respectively. Alprostadil use remained 
cost-saving versus lumbar sympathectomy in most of the scenarios evaluated 
through sensitivity analysis. cOnclusiOns: These results suggest alprostadil is a 
cost saving intervention when compared with lumbar sympathectomy for patients 
with CLI from the Mexican public health care perspective.
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Objectives: The objective of this pharmacoeconomic evaluation was to determine 
whether apixaban, compared to warfarin, dabigatran and rivaroxaban in patients 
suitable for vitamin K antagonists (VKA), or to aspirin in VKA-unsuitable patients, 
is a cost-effective treatment for the prevention of stroke or systemic embolism (SE) 
in adult patients with non-valvular atrial fibrillation (AF) with one or more risk fac-
tors. MethOds: A Markov model was constructed consisting of 18 health states, 
using a 6-week cycle length and a lifetime time horizon. Baseline characteristics were 
taken from a 2011 GPRD study. Clinical inputs were derived from a network meta-anal-
ysis of the efficacy and bleeding outcomes from the three warfarin-controlled trials 
ARISTOTLE, RE-LY and ROCKET-AF, and the single aspirin-controlled trial AVERROES. 
Local unit costs and utility data were assigned to the appropriate model health states 
to calculate total Quality-Adjusted Life Years (QALYs) and costs. Univariate and proba-
bilistic sensitivity analyses (PSA) were conducted. Results: Apixaban was associated 
with an ICER vs warfarin of € 11,087. Against the less-commonly used anti-coagulants, 
apixaban was cost-effective against each at the € 45,000 willingness-to-pay thresh-
old. Apixaban provided more QALYs than all other therapies. Compared to warfarin, 
apixaban produced savings in avoided cost of stroke, intracranial haemorrhage, INR 
monitoring, and bleeding. Apixaban was cost-effective across all patient subgroups 
of INR control (centre Time in Therapeutic Range) and CHADS2stroke risk categories 
1 and 2. One-way sensitivity analyses, scenario analyses, and probabilistic sensitivity 
analyses confirmed that the findings were robust to changes in key parameters. The 
probability that apixaban was the most cost-effective therapy at a willingness-to-
pay threshold of € 45,000 per QALY was 93% and 100% in the VKA-suitable and VKA-
unsuitable populations, respectively. cOnclusiOns: Apixaban can be considered 
cost-effective for the prevention of stroke and SE in people with non-valvular AF, at 
a threshold of € 45,000/QALY, under standard decision rules.
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Objectives: Stroke prevention is the main goal in treating patients with atrial 
fibrillation (AF). Treatment with anticoagulants, such as vitamin-K antagonists 
(VKAs; e.g. warfarin and cumarines), was demonstrated to be an effective strat-
egy. However, even though VKAs are the current standard therapy recommended 
by different guidelines, the significant risk of bleeding and the requirement for 
a regular monitoring are limiting its use. Apixaban is a novel oral anticoagulant 
(NOAC) associated with significantly lower hazard rates for stroke/systemic embo-
lism, major hemorrhage and discontinuations, compared to VKAs. This study evalu-
ated the cost-effectiveness (CE) of apixaban compared to VKAs in the base-case 
analysis and alternatively to other NOACs for stroke prevention in non-valvular 
AF patients in The Netherlands. MethOds: A global Markov model developed by 
United BioSource Corporation was modified to reflect the use of oral anticoagulants 
in The Netherlands. The model used efficacy data from a published indirect treat-
ment comparison of NOACs and cost data from Dutch costing studies as inputs. 
Following health states were included in the model: non-valvular AF, primary and 
recurrent ischemic and hemorrhagic stroke, systemic embolism, myocardial infarc-
tion, intracranial hemorrhage, other major and non-major bleedings, treatment 
patients suffering from chronic heart failure is a highly cost-effective health tech-
nology in the Polish setting, according to the criterion defined in Reimbursement 
Law. Robustness of this finding is demonstrated by the fact that cost-effectiveness 
is retained even at a price double vs base-case.
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Objectives: Large randomized clinical trials (RCT) evidenced the benefits of statins 
in reducing major cardiovascular events in patients with established coronary heart 
disease (CHD). These multinational trials are likely to provide internally valid evi-
dence. Cost-effectiveness analysis based on single trials costs and effects are common 
and represent the potential net benefit of an intervention in a well-controlled environ-
ment. The aim of this study is to systematically review the cost-effectiveness studies 
based on statins single trials in patients with previous CHD. MethOds: We searched 
to identify all literature relating to the cost-effectiveness of statins in the secondary 
prevention in patients with established CHD. Only studies with the effectiveness data 
extracted from a single RCT and clinical outcomes such as quality assessment, mor-
tality or cardiovascular events rate were included. The cost per QALY was classified 
according to the WHO, following three categories of cost-effectiveness, Highly cost-
effective, Cost-effective and Not cost-effective, adjusted with GDP per capita based 
on purchasing power parity (constant 2005 international USD). Results: Twenty-one 
studies were included in the final analysis, covering a period range from 1996 to 
2009. 7 large RCTs represented the origin of efficacy data. Most of studies assumed 
a full compliance, the Markov models were used in 11 out 21 studies. Time horizon 
ranged from 5 years to time life, with 10 years being the predominant choice. 9 studies 
performed a cost-utility analysis and showed the average cost per QALY, 8 of them 
classified as highly cost-effective and 1 cost-effective. Cost per QALY was sensitive for 
drug price, time horizon and event rates, 6 of this models models worked with com-
posite endpoints. cOnclusiOns: Statins are highly cost-effective in patients with 
CHD when effect size came from single well designed RCTs. Models heterogeneity 
and composite endpoints can decrease the robustness of the results.
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Objectives: It has been suggested that radiofrequency catheter ablation could take 
priority over antiarrhythmic drugs as first-line treatment of paroxysmal AF, due to 
better efficiency, and fewer serious side effects. The objective of this study was to 
evaluate the cost-effectiveness of treating paroxysmal atrial fibrillation with radi-
ofrequency catheter ablation as first-line treatment. MethOds: A decision-analytic 
Markov model was developed to study long-term effects and costs of catheter abla-
tion compared to antiarrhythmic drugs as first-line treatment. Results: Small, 
positive clinical effects were found in the overall population, a gain of an average 
0.06 quality-adjusted life years (QALYs) to an incremental cost of € 3033, resulting in 
an incremental cost-effectiveness ratio of € 50 570/QALY. However, the incremental 
cost-effectiveness ratio of a 45-year-old patient was approximately € 3434/QALY, 
while a 65-year-old costs € 108 937 per QALY. cOnclusiOns: Radio-frequency cath-
eter ablation as first-line treatment is a cost-effective strategy for younger patients 
with paroxysmal atrial fibrillation. However, the cost-effectiveness of using catheter 
ablation as first-line therapy in older patients is uncertain, and in most of these 
cases antiarrhythmic drug therapy should be attempted before catheter ablation.
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Objectives: Portugal is facing an economic crisis that demands a tight control over 
all hospitals’ expenditures, namely with medical devices, whose market price is not 
yet regulated or documented. This study aims to describe the number and value of 
the Active-Implantable Cardiac Devices (AICD) bought by Portuguese hospitals in 
2011, as well as to quantify potential savings that can be obtained shifting utilisation 
from higher to lower prices. MethOds: In February 2012, 42 hospitals were asked 
by INFARMED – National Authority of Medicines and Health Products, IP, about the 
number, type and value of the AICD acquired, using an ad-hoc developed software. 
Potential savings analysis was performed at two levels: AICD sub-groups (according 
to Portuguese Medical Device Nomenclature) and individual device reference. Within 
each level, three cost-minimization scenarios were conceptualized based on the 
minimum price reported (scenario 1), the average between the average price and 
the minimum one (scenario 2) and the average price (scenario 3). Results: During 
2011, 73.8% of the hospitals enrolled (n= 31) bought AICD, comprising 16,815 devices, 
at a cost of 40,217,411 euros. In numbers, the most common AICD were pacemakers 
(44.8%), whereas cardioverter-defibrillators were related to a higher expenditure 
ratio (51.5% of total cost). Based on the AICD sub-groups analysis, the potential sav-
ings were 14.5 million euros in scenario 1 (44.1% of total cost), 7.4 million euros in 
scenario 2 (22.5%) and 1.8 million euros in scenario 3 (5.3%). Following this scenario 
order, the device reference approach estimated savings of 6.2 million euros (18.8%), 
3.4 million euros (10.3%) and 1.1 million euros (3.3%), respectively. cOnclusiOns: 
Significant potential savings were found, being greater when analysing AICD sub-
groups, assuming equal efficiency and safety for all devices within these clusters. 
Despite scenario 1 higher savings, scenario 2 seems the most realistic and feasible, 
when trying to accomplish a sustainable health care system.
